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Pharmacokinetic study of oral Once Daily Tramadol compared to Immediate Release Dosage Form of Tramadol in dogs.

Abstract
Background: Tramadol is used as an analgesic in dogs. A regimen of 3-4 times daily, 2-5 mg/kg is used, but hard to follow. Therefore the aim of this study is to determine whether the immediate release (IR) regimen can be replaced by once daily (OD) formulation, by comparison of the AUC0-24h.
Methods: a crossover design with 6 female Beagle dogs. Four times daily 50 mg (2.96 – 3.76 mg/kg) was compared to once daily 200 mg (11.83 – 15.04 mg/kg). Blood samples were analyzed for tramadol, M1, M2 and M5 with a validated LC-MS method.
Results: No M1 was found in the dogs and tramadol concentrations are low for IR en OD (59 μg/L and 172 μg/L respectively). There was no statistical significant difference in the AUC0-24h between the two dosage forms. Especially M2 was found. 





Tramadol hydrochloride, 1RS,2RS-2[(dimethylamino)-methyl]-1-(3-methoxyphenyl)cyclohexanol, is a centrally acting, synthetic analgesic. Tramadol is used in chronic pain and moderate to severe pain, for example postoperative- and benign pain. Non-steroidal anti-inflammatory drugs (NSAIDs) are the only registered drugs in the Netherlands for post-operative analgesia in dogs.3 However, in some cases there is a contra-indication for NSAIDs. For example in patients with renal or gastro-intestinal problems, or when a non-opioid analgesic is not sufficient at its maximum dose. In these cases tramadol is often the drug of choice.  As tramadol is not registered as veterinary drug, immediate release (IR) capsules, registered for humans are used.15 The dosage used in dogs is 3 to 4 times daily 2 – 5 mg/kg.19,23 Yazbek et al have shown that tramadol offers equal or significantly better analgesia in post-operative pain in dogs, compared to NSAIDs. 27

The analgesic mechanism of tramadol is mainly achieved by acting on the mu-receptor, but also by inhibiting reuptake of serotonin and norepinephrine.13
The different isomers of tramadol HCl have a different contribution to the analgesic effect. (+)-Tramadols affinity for µ-receptor binding is 20 times larger than that of (-)-tramadol. Furthermore, (+)-transtramadol interacts with adrenergic and serotonergic receptors, while (-)-tramadol only interacts with adrenergic receptors. 22,28
In the liver, tramadol is metabolized by cytochrome P450 (CYP) enzymes8 into phase I metabolites, like O-desmethyltramadol (M1), N-desmethyl-tramadol (M2) and N,O-didesmethyltramadol (M5), all of which are also racemic mixtures13 . Although in different species investigated, the biotransformation of tramadol is qualitatively the same. The metabolites are formed in different quantities2,11,15,16. In canines mainly M2 and M5 are formed9,10,12,15, while in humans high levels of M1 are found1,24. This is of interest, because M1 is the only metabolite that has a more potent μ-receptor binding than tramadol2,9,11,12,13,22. In animal models, (+)-M1 has 6 times the potency of tramadol in providing analgesia and 200 times more potent μ-receptor binding22. (+)-M1 also interacts with adrenergic and serotonergic receptors. By inhibiting the reuptake of serotonin and noradrenalin, tramadol and M1 potentiate their own opioid effect22.  M2 and M5 are qualified as inactive metabolites. (+)M5 has a higher affinity for the μ-receptor than (+)-tramadol, but does not penetrate the blood brain barrier13,29. The µ-receptor binding of tramadol is approximately 10-fold less than that of codeine and 6000-fold less than that of morphine. M1 affinity is about 300 times stronger than tramadol, but still has a lower affinity for the receptor than morphine. This accounts for the fact that few adverse events are found in the therapeutic use of tramadol, compared to the effects such as nausea and vomiting caused by other opioids13. Also constipation, a very common side effect of opioids, is minor with tramadol. Intravenous tramadol had a smaller inhibitory effect on gastric emptying compared to codeine en morphine5,13.
These characteristics, of being well-tolerated, less dependence and minor adverse effects, make tramadol a very useful and save-to-use analgesic, which has proven its effect on moderate to severe pain in humans13.

The dose given in dogs is higher than in humans. Dogs receive 2-5 mg/kg 3-4 times daily, while in humans 50-100 mg, 3-4 times daily is used. With an average weight of 70 kilograms, that is 0.7-1.4 mg/kg, 3-4 times daily7,19. 
The elimination half-life of tramadol after oral dosing is 5.5 hours in man13,15, opposed to 1.71 ± 0.12 h in dogs7,15,19. The systemic clearance is about 5 times faster in dogs compared to humans12,15,29. This explains the higher dose needed in dogs to establish the same analgesic effect.
Although a 4-times daily schedule appears to be sufficiently analgesic20,27, this regimen is hard to follow for a lot of dog owners.
A review study in humans found a mean compliance of 71 ± 17%, which declined as the number of doses per day increased4.  In the once-daily routine, a compliance of 79 ± 14% was found, compared to 51 ± 20% with a four times daily routine, which is a significant difference4.  A study into owner compliance found that, although 70-80% of the owners administered the right number of doses each day, only 20-34% gave doses at the correct time18. Therefore, sufficient pain relief cannot be guaranteed. Because of the need for continuous pain relief during a day and for user friendliness, there are also controlled release tablets registered for human use. These need to be administered only once daily (OD), thereby reducing adverse effects, such as nausea, dizziness, drowsiness and fatigue, due to abrupt peaks in plasma concentrations. The risk of break-through pain is also diminished because of the uniformity of tramadol plasma concentrations6. A study with patients suffering from chronic non cancer pain, reported a significant reduction in pain intensity with controlled release OD tramadol  compared  to IR tramadol2.






Four adult female beagle dogs and two adult female Beagle X Bedlington terrier cross breed dogs, weighing between 13.3 and 16.9 kilograms are used in this study. The mean age of these dogs is 6 years (4-7 years).  The study protocol was approved by the Animal Ethical Committee of the Utrecht University.

Experimental protocol
The setup of this study is a cross-over design. The order of the two treatments, IR-OD or OD-IR, was randomly assigned. Food was given once a day in the morning. Water was available ad libitum. 
For comparable results between the two dosage forms the concentrations of tramadol needs to be measured at steady state. On the first day, the three dogs of the IR-OD group received one tramadol IR capsule 50 mg (2.96 – 3.47 mg/kg ) every 6 hours, 5 times total. The half life of tramadol in dogs is 1.71 hours, administration of 50 mg IR tablets 4 times daily during 24 hours, to approach a steady state.  After the fifth capsule, blood samples are collected at 15/30/45/60/90 and 120 minutes and 4 and 6 hours. At day three and four, tramadol Once Daily 200 mg tablet (11.83 – 13.89 mg/kg per day) is administered. After the second dose, blood samples are collected at 30/60/90 minutes and 3/6/9/15/24 hours. 
The three dogs of the OD-IR group received tramadol OD 200 mg tablet, once daily (12.12-15.04 mg/kg/day) during 48 hours. After the second dose, blood samples are collected at 30/60/90 minutes and 3/6/9/15/24 hours.
Following a 48 hours break, one tramadol IR capsule 50 mg (3.03-3.76 mg/kg) every 6 hours 5 times total, is administered. After the fifth dose, blood is collected at 15/30/45/60/90 and 120 minutes and 4 and 6 hours. 

Blood sampling




















To 100 µl serum 750 µl precipitating reagent is added and a sediment was formed. The precipitating reagent consists of 0.04 mg/L cyanoimipramine (internal standard for basic compound), 0.4 mg/L butobarbital (internal standard for acid compounds), 160 ml/L methanol and 840 ml/L acetonitrile. The samples were mixed for 1 minute with a multitube vortexer (Lab-tek Corportion Ltd). Subsequently they were frozen by placing them into the freezer for 30 minutes, followed by shaking them again with the vortex for 1 minute. Finally the samples were centrifuged at 11000 rpm for 5 minutes and collected in the auto sampler of the LC-MS system. 

Method validation
The method validation is implemented as described in appendix 1. The validation results demonstrate that the response for T, M1, M2 and M5 was linear from 5 till 3000 µg/L, the regression coefficients (R2) were 0.99950, 0.99868, 0.99907 and 0.99837 respectively. The accuracy and precision are within the maximum tolerated bias and coefficient of variation (CV) (20% for LLOQ and 15% for the other concentrations), as shown in appendix 2. Also the freeze-thaw stability suffice, this is also summarized in appendix 2. The limit of quantification (LLOQ) for as well tramadol as M1, M2 and M5 is 5 μg/L.
The validation process is accomplished in human serum while the samples are in dogs serum. So a cross-validation to dogs’ serum is required for validated results of bloodsamples from dogs. Also the results of the cross-validation met the requirements (an overall bias < 15%), see appendix 3. 

Pharmacokinetic analysis 










After oral administration of tramadol immediate release and the once daily formulation, tramadol was largely metabolized in M2 and M5. The metabolite M1 is also formed, but in very small quantities in comparison to M2 and M5. In the present study, M1 stayed below the lowest limit of quantification (< 5 µg/ml) in all dogs, data not shown. The plasma concentration time curves of tramadol immediate release and once daily are shown in figure 3 and 4. The shape of the graphs differs between the six dogs, especially in the OD formulation. The concentrations of IR tramadol found in dog 5 are much higher than in other dogs, maximum concentration of 220 μg/L in dog 5 versus ± 40 μg/L in the others, see also table 1. After administering the OD formulation, tramadolconcentration were not found in dog 1, while the concentration of tramadol in dog 4 rises high above the others (380 μg/L). As expected, the time to reach maximum concentration (Tmax) of the OD formulation is much longer than of the IR formulation, 9 hours versus 1.5h respectively.

Figure 3: concentration time curve tramadol IR (n=6)		Figure 4: concentration time curve tramadol OD(n=5)	
*For dog 3 and 6 concentrations of tramadol at 360 minutes	*For dog 6 only at six, nine and 15 hours the 
are below LLOQ     	concentration tramadol is above LLOQ
*For dog 3 the concentration of tramadol at 24 hours is below LLOQ
*For dog  1 the concentration of tramadol did not rise above the LLOQ





Figure 5: concentration time curve M2 IR (n=6)	Figure 6: concentration time curve M2 OD (n=6)
*The concentration of M2 in dog 1 at 24 hours is below LLOQ					             
The plasma concentration curves for M5 are shown in figure 7 for IR and figure 8 for OD. As with the other IR-curves, the shapes between the different curves are comparable, while those in the OD-curves are not. The IR concentration time curve of M5 shows the highest concentrations in dog 5 and the lowest in dog 1.  Also in the OD concentration time curve the lowest concentration of M5 is found in dog 1. 

Figure 7: concentration time curve M5 IR (n=6)			Figure 8: concentration time curve M5 OD (n=6)
*The concentration of M5 in dog 1 at 24 hours is below LLOQ





Figure 9: averages of T, M2 and M5 of IR formulation	        	 Figure 10: averages of T, M2 and M5 of OD formulation
	  						 









*: statistic significant difference

As shown in the table above, the AUC’s of tramadol, M2 and M5 do not differ significantly between IR en OD. However the AUC for tramadol OD is 2.5 times larger than for tramadol IR, while the AUC for OD M2 is 1.5 times smaller than for IR. The AUC for M5 is approximately the same for both formulations. 
The maximum serum concentration of tramadol (Cmax) in the once-daily formulation is higher than in the IR-formulation, 172 µg/L versus 59 μg/L respectively, though it is not statistic significant (p= 0.225). On the other hand the Cmax~for M2 and M5 reach approximately the same level in both formulations. The not for absorption corrected elimination half time (T1/2) differs, as would be expected, between the two dosage forms and between tramadol and its metabolites. The T1/2 for tramadol does not differ significantly for the different regimens, but they do for M2 and M5. The Tmax of tramadol, M2 and M5 differs statistically significant between de IR and OD formulation, p=0.042 , p=0.028 and p=0.027 respectively. 




























Our study aimed to find out whether the human OD formulation of tramadol is bioequivalent to the four times daily immediate release regime in dogs.  This bioequivalence has to be demonstrated by no significant difference in the 24 hours AUC of tramadol between the IR and OD formulation.  

The 24 hours AUC of IR tramadol and the OD formulation analyzed in this study show no statistical differences between both dosage forms.  Also the Cmax for tramadol, M2 and M5 does not differ significantly between IR and OD. The T1/2 for tramadol does not differ significantly, but for M2 and M5 it does. Although not significantly different, the T1/2 of tramadol for the IR formulation is about twice that of the OD formulation. Further on, we will discuss this result. Based on that, we could state that 50 mg IR capsule tramadol 4 times daily is replaceable by 200 mg OD tablet of tramadol.  However, these results should be interpreted with care. 

Firstly because M1, assumingly the only active metabolite in humans and 200 times more potent than tramadol, is found in the present study in unquantifiable amounts (<5 μg/L). Higher levels of M2 (130 μg/L) and M5 (36 μg/L) were found, which agrees with studies in dogs by Kukanich and Giorgi9,10,12,15. Also horses formed M1 in unquantifiable amounts en higher levels of M2 and M511. Despite of this lack of M1, studies by Pogge and Yazbek have shown evidence of similar or improved analgesia of tramadol compared to NSAIDs20,27. Also, observations by experts worldwide have shown tramadol to be clinically relevant in analgesia. One of the possible explanations of this analgesic effect is that other metabolites are (more) active, like M2, M5 or other non studied metabolites. Another possibility is that lower concentrations of T and M1 are therapeutic in dogs. 
The low amount of M1 can be explained by the so-called flip-flop effect9,10,12,15, in which the elimination of M1 or metabolism of M1 into other metabolites, is faster than the formation of this metabolite (see figure 1). The shorter half-life of tramadol in dogs compared to humans proves that elimination and metabolism of tramadol is faster in these species. Possibly in dogs and other animals the assumption of M1 and tramadol as only active compounds is rejectable. The concentrations of M1 below LLOQ, low levels of tramadol and higher levels of M2 and M5 combined with the proven effectiveness of tramadol in dogs in daily practice suggests that also M2 and M5 are possible active metabolites. M2 penetrates through the blood-brain-barrier (BBB) where it can bind to μ-receptors. Although M5 doesn’t pass the BBB, because it high polarity (Grond), it might be effective, because its affinity for the peripherical μ-receptor17. Mousa et al.17 demonstrated that μ-receptors are formed peripherally at places of chronic pain. Otherwise these metabolites could be effective by serotonergic and/or adrenergic effects. 
The efficacy of the concentration of tramadol could be questioned. The Cmax of tramadol of 59 μg/L is far below the therapeutic concentration of tramadol in humans (298 μg/L). Only once a concentration of tramadol of over 298 μg/L is reached in a dog during this study. However there are no therapeutic concentrations of tramadol or any metabolites defined for dogs. Based on the proven effectiveness of tramadol IR, we can assume that the concentrations of tramadol, M2 and M5 measured from the IR tablets in this study are effective. Given the fact that not only the AUC but also the Cmax of tramadol, M2 and M5 in the OD form are increased compared to the IR formulation, the OD formulations reaches concentrations above the Cmax of the IR formulation, and should be effective.

Secondly, although the 24 hours AUC of tramadol in both dosage forms doesn’t differ statistically significant, the AUC of the OD regime is even 2.5 times larger than the AUC of de IR regime. The group of dogs used in this study is probably too small, so this makes the probability of obtaining statistically significant differences also quite small, even more so because the inter-individual differences are quite large. By using the Wilcoxon Signed Rank test on every parameter, there is always a 5% change of measuring in the outskirts of the distribution in every test. These pharmacokinetic differences between dogs could be explained in different ways. 
Primary, feeding could have an influence on the absorption of tramadol.  The dogs were fed once a day in the morning. However, the way the dogs were housed influences the time of food intake. Dogs, housed individual, ate the food during the whole day, while dogs sharing a kennel consume their food at once. Giorgi et al. found that food intake did not have a significant effect on biological availability in horses and Raber found the same for people, however in dogs no such reports were found11,21.
Also the metabolism of tramadol and its metabolites seems to influence the pharmacokinetic profile. For example, in one dog  low amounts of tramadol were found in IR formulation and in the OD formulation, tramadol even stayed undetected in this dog, also the concentrations of M2 and M5 were rather low. Since CYP2D enzymes are known to be polymorphic, this dog may be an extensive/ultra-rapid metabolizer. In the other dogs metabolism rates could play a role in the differences between pharmacokinetic profiles as well.  Beagle dogs are thought to have lower amounts of CYP2D-enzymes, which metabolize tramadol to M1. The metabolism rate of CYP2B and CYP3A in these dogs is higher than that of CYP2D, so more M2 is formed and more M1 and M2 is transformed to M514. Though Kukanich et al.15 also used beagle dogs for their study in tramadol, the choice of beagle dogs for this research could be questioned. Some researchers have found gender differences in the expression of CYP450 enzymes in humans. Besides, females usually have lower body weight and a higher fat percentage, which influences volume of distribution. So using only female dogs, might show different results compared to when male or mixed gender subjects are used25,26.

Finally the dosage interval used in dogs is based on the intervals used in humans. However, elimination half-time for tramadol in dogs is remarkably shorter than in human patients, 1.7 hours versus 5.5-6 hours respectively 13,15. Therefore one could question whether or not dosing tramadol 4 times a day in the dog is sufficient. The mean elimination half-life of tramadol in the IR formulation is about half of the elimination half-life of tramadol in the OD formulation. The T1/2 of M2 and M5 are larger for OD than for IR and they differ statistically significant from each other, as can be expected when using an IR and an OD formulation. The same goes for the Tmax of tramadol and its metabolites. Based on that, one could speculate that the dosage interval can be half of that used with IR formulation. This would mean that the OD 200 mg tablet for humans can be used as twice daily tablets for dogs. This could however create a risk of overdosing.





In summary the OD formulation of tramadol is compared to the IR formulation for the first time. The AUC0-24h, Cmax and T1/2 for T, M2 and M5 do not differ significantly between the two dosage forms, excepting the T1/2 of M2 and M5. Based on these results we state that the 50 mg tramadol capsule (four times daily) is replaceable by 200 mg of OD tramadol. 
However, we have only used tramadol, M1, M2 and M5 as parameters, while possibly other metabolites are active in the dog. We assumed that not only M1 is an active metabolite but also others could be active. Further research in efficacy of different metabolites has to be done to prove this assumption. 
Because the therapeutic concentrations of tramadol and its metabolites in dogs are unknown, the minimum and maximum active concentration has to be determined before we could state that administrating OD tablets, once or twice daily, is effective. 
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For method validation two stock solution, stock solution A and B, were prepared by weighing about 1 mg of all components (T, M1, M2 and M5) and solving them in 10 ml blanc human EDTA blood. Resulting in concentrations of all components in the stock solution about 100 mg/L. 
The calibration curve was prepared from stock solution A. Eight calibration points were used to determine linearity at three different days, these concentrations were 5/25;50;100;200;400;800;1200; 1500 μg/L. For each component a calibration curve was analyzed and the measured regression coefficient (R2) has to be > 0.998 to met the criteria for linearity.  
Stock solution B was used for the preparation of validation pools. This stock was diluted till ‘high’ (1200 μg/L), ‘medium’ (400 μg/L) and a ‘low’ (75 μg/L) concentrations, which were used for determination of the accuracy and precision.  Also a pool for the lower limit of quantification (LLOQ) (5 μg/L) and a dilution pool (over-curve) of 3000 μg/L were prepared from stock B. The over-curve dilution consisted of a single concentration of at least two times the concentration of the highest stock (1200 μg/L).  All concentrations were measured in 5-fold in three separate runs on separate days for determination of the accuracy, precision and over-curve dilution. 
Stabilities of tramadol and its metabolites were assessed at room temperature, in the autosampler and during 3 freeze-thaw cycles. 

Validation was performed with a maximum tolerated bias and coefficient of variation (CV) of the LLOQ of 20% and 15% for the other validation concentrations. For each validation, concentration bias and CV were calculated per run. Within-run, between-run and overall CVs were calculated using one-way ANOVA.








Table 1: validation results of tramadol, M1, M2 and M5 in human serum
Component	Regression coefficient, linear range (µg/L)	Concentration (µg/L)	Within run(%)	Between run (%)	Overall CV 
(%)	Overall bias (%)
Tramadol	0.99950(5.00-1500)	LLOQ (5.0)LOW (75.0)MED (400.0)HIGH (1200.0)DIL (3000.0)F/T stab LOWF/T stab HIGHRT stab 152 h LOWAS stab 46 h LOWAS stab 114 h LOWRT stab 152 h HIGHAS stab 46 h HIGHAS stab 114 h HIGH	4.64.33.02.81.43.93.63.14.05.01.43.25.1	9.40.00.90.40.71.82.8NANANANANANA	10.54.33.12.81.54.34.5NANANANANANA	1.510.313.07.114.014.210.013.814.518.16.814.312.6
M1	0.99868 (5.00-1500)	LLOQ (5.0)LOW (75.0)MED (400.0)HIGH (1200.0)DIL (3000.0)F/T stab LOWF/T stab HIGHRT stab 152 h LOWAS stab 46 h LOWAS stab 114 h LOWRT stab 152 h HIGHAS stab 46 h HIGHAS stab 114 h HIGH	6.14.93.63.33.44.04.23.64.53.92.24.64.9	8.23.41.30.80.00.01.6NANANANANANA	10.26.03.83.43.44.04.5NANANANANANA	-1.210.511.06.713.013.28.014.112.313.75.712.47.6
M2 	0.99907(5.00-1500)	LLOQ (5.0)LOW (75.0)MED (400.0)HIGH (1200.0)DIL (3000.0)F/T stab LOWF/T stab HIGHRT stab 152 h LOWAS stab 46 h LOWAS stab 114 h LOWRT stab 152 h HIGHAS stab 46 h HIGHAS stab 114 h HIGH	5.83.53.92.42.23.83.54.62.34.61.23.74.6	8.43.10.40.71.71.02.0NANANANANANA	10.34.63.92.52.73.94.0NANANANANANA	-2.89.411.35.113.012.87.014.015.513.66.911.38.9
M5	0.99837 (5.00-1500)	LLOQ (5.0)LOW (75.0)MED (400.0)HIGH (1200.0)DIL (3000.0)F/T stab LOWF/T stab HIGHRT stab 152 h LOWAS stab 46 h LOWAS stab 114 h LOWRT stab 152 h HIGHAS stab 46 h HIGHAS stab 114 h HIGH 	6.95.03.62.92.74.14.73.44.42.87.24.14.3	8.90.00.00.34.00.00.0NANANANANANA	11.35.03.62.94.84.14.7NANANANANANA	-3.710.614.09.81016.710.019.015.115.913.212.58.2






Table 2: cross-validation results tramadol, M1, M2 and M5 in dogs serum. 
Component	Concentration (µg/L)	Overall CV 
(%)	Overall bias (%)
Tramadol	LLOQ (25.0)LOW (75.0)MED (400.0)HIGH (1200.0)DIL (3000.0) 	2.24.73.53.22.3	7.012.011.38.88.1
M1	LLOQ (25.0)LOW (75.0)MED (400.0)HIGH (1200.0)DIL (3000.0)	4.53.93.73.73.2	-1.812.311.8-4.69.6
M2 	LLOQ (5.0)LOW (75.0)MED (400.0)HIGH (1200.0)DIL (3000.0)	4.14.33.92.91.4	4.77.99.04.013.8
M5	LLOQ (5.0)LOW (75.0)MED (400.0)HIGH (1200.0)DIL (3000.0)	5.45.72.33.23.0	-0.59.011.714.813.7









